Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Early stage hormone receptor positive breast cancer is typically treated with adjuvant
endocrine therapy in order to decrease risk of breast cancer recurrence and to improve
overall survival from the disease. Typical agents used for treatment include tamoxifen and
the aromatase inhibitors. In postmenopausal women, aromatase inhibitor therapy is
increasingly common because it is associated with fewer long-term serious toxicities compared
to tamoxifen. However, aromatase inhibitors cause arthralgias in 40-50% of patients, which
can influence adherence to therapy and can lead to treatment discontinuation in a minority of
cases. The mechanism underlying development of this toxicity remains unclear, and predictors
of who will develop these symptoms remain undefined. Initial reports suggest that grip
strength decreases during aromatase inhibitor therapy, and that body-mass index may influence
development of this symptom. Therefore, this longitudinal study has been developed to
determine change in grip strength over time in women treated with aromatase inhibitors and
tamoxifen, as well as to identify potential associations between change in grip strength and
BMI. Patient self-reported symptoms will also be collected. A total of 115 women with early
stage breast cancer who are initiating therapy with either an aromatase inhibitor or
tamoxifen will be enrolled.
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center